Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cell count may reveal who faces worst outcomes in rare autoimmune disease

NCT ID NCT05989399

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined whether the level of neutrophils, a type of white blood cell, in the blood can help predict how severe antisynthetase syndrome (ASyS) will be. ASyS is a rare autoimmune disease that can cause muscle inflammation, lung disease, and other symptoms. Researchers looked at data from 89 patients to see if a high neutrophil count at diagnosis was linked to more severe disease. The goal is to find a simple, widely available test to identify high-risk patients early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to identify which patients with antisynthetase syndrome are at risk for severe disease, helping doctors intervene earlier.
What could go wrong
This is a small, retrospective study that only looks back at existing data. The findings may not apply to all patients and need to be confirmed in larger, prospective trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

89 people

The number who actually took part.

Started

Jan 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with ASyS diagnosis between January 2010 and December 2022

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with ASyS diagnosis according to Connors criteria Exclusion Criteria: * Active infection at ASyS diagnosis * Evolutive cancer at ASyS diagnosis * Corticosteroid therapy initiation before circulating neutrophils evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antisynthetase syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

antisynthetase syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antisynthetase syndrome

Contacts and locations

Locations

  • CHU Nancy

    Nancy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.